N-棕榈酰-O-膦酰-L-丝氨酸 | 155915-46-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-棕榈酰-O-膦酰-L-丝氨酸
• 英文名称: L-Naspa
• 英文别名: (2S)-2-(hexadecanoylamino)-3-phosphonooxypropanoic acid
• CAS: 155915-46-1
• 化学式: C₁₉H₃₈NO₇P
• 分子量: 423.5
• InChiKey: HSMUPNYJCMYKJH-KRWDZBQOSA-N

物化性质

• 溶解度：
  在DMSO中的溶解度为10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  28
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• Gas-filled stabilized particles and methods of use
  申请人：Children's Medical Center Corporation

  公开号：US10577554B2

  公开（公告）日：2020-03-03

  Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.

  本文提供了各种充满气体的颗粒，这些颗粒具有封装气体的稳定膜。此外，还介绍了药物组合物、使用和处理方法以及制备方法。
• Lysophosphatidic acid analogs and inhibition of neointima formation
  申请人：——

  公开号：US20040204383A1

  公开（公告）日：2004-10-14

  The phospholipid growth factor lysophosphatidic acids (LPAs) containing unsaturated fatty acids (18:1, 18:2 and 20:4) and fatty alcohols containing hydrocarbon chains with more than 4 carbons were capable of inducing a rapid formation of neointima, an initial step in the development of atherosclerotic plaque. LPAs with saturated fatty acids did not induce neointima formation. A Peroxisome Proliferator-Activated Receptors gamma (PPAR&ggr;)-specific agonist Rosiglitasone also induced a profound formation of neointima. GW9662, a selective and irreversible antagonist of PPAR&ggr;, abolished LPA- and Rosiglitazone-induced neointima formation, indicating that LPA-induced neointima formation requires the activation of PPAR&ggr;. These data suggest that LPA analogs that bind to but do not activate downstream signaling of PPAR&ggr; or antagonists of PPAR&ggr; that inhibit PPAR&ggr; signaling would be useful in the prevention and/or treatment of neointima formation and atherosclerosis.

  磷脂生长因子溶血磷脂酸（LPAs）含有不饱和脂肪酸（18:1、18:2 和 20:4）和碳氢链超过 4 个碳原子的脂肪醇，能够诱导新内膜的快速形成，这是动脉粥样硬化斑块发展的第一步。含有饱和脂肪酸的 LPA 不会诱导新生内膜的形成。一种过氧化物酶体增殖激活受体γ（PPAR&ggr;）特异性激动剂Rosiglitasone也能诱导新生内膜的快速形成。GW9662是一种选择性和不可逆的PPAR&ggr;拮抗剂，它能消除LPA和罗格列酮诱导的新生血管形成，表明LPA诱导的新生血管形成需要PPAR&ggr;的激活。这些数据表明，与 PPAR&ggr; 结合但不激活 PPAR&ggr; 下游信号传导的 LPA 类似物或抑制 PPAR&ggr; 信号传导的 PPAR&ggr; 拮抗剂将有助于预防和/或治疗新内膜形成和动脉粥样硬化。
• EP1613298A2
  申请人：——

  公开号：EP1613298A2

  公开（公告）日：2006-01-11